Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure

Journal of the American Veterinary Medical Association

Volumn 212, Issue 4, 1998, Pages 521-528

  Cowgill, Larry D ^a   James, Katherine M ^a,b,d   Levy, Julie K ^a,e   Browne, Jeff K ^c   Miller, Allan ^c   Lobingier, Robert T ^a,f   Egrie, Joan C ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Cat Hospital   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e University of Florida College of Veterinary Medicine   (United States)

^f Veterinary Diagnostic Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CREATININE; DRUG ANTIBODY; HEMOGLOBIN; IRON; NITROGEN; PHOSPHATE; POTASSIUM; RECOMBINANT ERYTHROPOIETIN; SODIUM; UREA;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CAT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DOG; ERYTHROCYTE COUNT; ERYTHROPOIESIS; HEMATOCRIT; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY; NONHUMAN; RETICULOCYTE COUNT; SEIZURE; SUBCUTANEOUS DRUG ADMINISTRATION;

ANEMIA; ANIMALS; BLOOD CELL COUNT; BLOOD CHEMICAL ANALYSIS; BLOOD PRESSURE; BONE MARROW; CAT DISEASES; CATS; DOG DISEASES; DOGS; ERYTHROCYTE INDICES; ERYTHROPOIETIN; FEMALE; HEMATOCRIT; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; RECOMBINANT PROTEINS; SEIZURES;

ANIMALIA; CANIS FAMILIARIS; FELIS CATUS;

EID: 0032519282     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Eschbach JW, Haley NR, Adamson JW. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin. Contrib Nephrol 1990;78:24-37.
2. Hakim RM, Lazarus M. Biochemical parameters in chronic renal failure. Am J Kidney Dis 1988;11:238-247.
3. Polzin DJ, Osborne CA, Bartges JW, et al. Chronic renal failure. In: Ettinger SJ, Feldman EC, eds. Textbook of veterinary internal medicine. Diseases of the dog and cat. 4th ed. Philadelphia: WB Saunders Co, 1995;1734-1760.
4. DiBartola SP, Rutgers HC, Zack PM, et al. Clinicopathologic findings associated with chronic renal disease in cats: 74 cases (1973-1984). J Am Vet Med Assoc 1987;190:1196-1202.
5. Giger U. Erythropoietin and its clinical use. Compend Contin Educ Pract Vet 1992;14:25-34.
6. King LG, Giger U, Diserens D, et al. Anemia of chronic renal failure in dogs. J Vet Intern Med 1992;6:264-270.
7. Cook SM, Lothrop CD. Serum erythropoietin concentrations measured by radioimmunoassay in normal, polycythemic, and anemic dogs and cats. J Vet Intern Med 1994;8:18-25.
8. Cowgill LD. Management of anemia associated with renal failure. In: August JR, ed. Consultations in feline internal medicine. 2nd ed. Philadelphia: WB Saunders Co, 1994;331-338.
9. Cowgill LD. Medical management of the anemia of chronic renal failure. In: Osborne CA, Finco DR, eds. Canine and feline nephrology and urology. Baltimore: The Williams & Wilkins Co, 1995;539-554.
10. Erslev AJ. Erythropoietin. N Engl J Med 1991;324: 1339-1344.
11. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-78.
12. Bommer J, Alexiou C, Muller-Buhl U, et al. Recombinant human erythropoietin therapy in haemodialysis patients - dose determination and clinical experience. Nephrol Dial Transplant 1987;2:238-242.
13. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992-1000.
14. Sundal E, Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicenter study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant 1989;4:979-987.
15. Adamson JW, Eschbach JW. Treatment of the anemia of chronic renal failure with recombinant human erythropoietin. Annu Rev Med 1990;41:349-360.
16. Bennett WM. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol 1991;1: 990-998.
17. Deniston OL, Luscombe FA, Buesching DP, et al. Effect of long-term epoetin beta therapy on the quality of life of hemodialysis patients. ASAIO J 1990;36:M157-M160.
18. Evans RW, Rader B, Manninen DL, et al. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990;263:825-830.
19. Wolcott DL, Marsh JT, La Rue A, et al. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 1989;14:478-485.
20. Cowgill LD. Pathophysiology and management of anemia in chronic progressive renal failure. Semin Vet Med Surg (Small Anim) 1992;7:175-182.
21. Eschbach JW, Adamson JW. The pathophysiology and treatment of the anemia of chronic renal failure. In: Gonick HC, ed. Current nephrology. St Louis: Mosby Year-Book Inc, 1991;259-291.
22. Abraham PA, St Peter WL, Redic-Kill KA, et al. Controversies in determination of epoetin (recombinant human erythropoietin) dosages. Clin Pharmacokinet 1992;22:409-415.
23. Bommer J, Barth H-P, Zeier M, et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol 1991;88:136-143.
24. Kaupke CJ, Butler GC, Vaziri ND. Effects of recombinant human erythropoietin on platelet production in dialysis patients. J Am Soc Nephrol 1993;3:1672-1679.
25. Ishibashi T, Koziol JA, Burstein SA. Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro. J Clin Invest 1987;79:286-289.
26. Berridge MV, Fraser JK, Carter JM, et al. Effects of recombinant human erythropoietin on megakaryocytes and on platelet production in the rat. Blood 1988;72:970-977.
27. Van Wyck D. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management. Semin Nephrol 1989;9:21-24.
28. Van Wyck DB. Iron management during recombinant human erythropoietin therapy. Am J Kidney Dis 1989;14(Suppl 2): 9-13.
29. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990;300:573-578.
30. van de Borne P, Tielemans C, Vanherweghem JL, et al. Effect of recombinant human erythropoietin therapy on ambulatory blood pressure and heart rate in chronic haemodialysis patients. Nephrol Dial Transplant 1992;7:45-49.
31. Eschbach JW, Egrie JC, Downing MR, et al. The safety of epoetin-alpha: results of clinical trials in the United States. Contrib Nephrol 1991;88:72-80.
32. Powe NR, Griffiths RI, Watson AJ, et al. Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and cost of dialysis patients. J Am Soc Nephrol 1994;4:1455-1465.
33. Goodnough LT, Rudnick S, Price TH, et al. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 1989;321:1163-1168.
34. Satoh K, Masuda T, Ikeda Y, et al. Hemodynamic changes by recombinant erythropoietin therapy in hemodialyzed patients. Hypertension 1990;15:262-266.
35. Kamata K, Marumo F, Onoyama K. Hemodynamic mechanism of the elevation in blood pressure following the improvement of anemia with recombinant human erythropoietin. Jpn Circ J 1991;55:649-656.
36. Neff MS, Kim KE, Persoff M, et al. Hemodynamics of uremic anemia. Circulation 1971;43:876-883.
37. Steffen HM, Brunner R, Muller R, et al. Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin. Contrib Nephrol 1989;76:292-298.
38. Wen D, Boissel J-PR, Tracy TE, et al. Erythropoietin structure-function relationship: high degree of sequence homology among mammals. Blood 1993;82:1507-1516.
39. Goto M, Murakami A, Akai K, et al. Characterization and use of monoclonal antibodies directed against human erythropoietin that recognize different antigenic determinants. Blood 1989;74: 1415-1423.
40. D'Andrea AD, Szklut PJ, Lodish HF, et al. Inhibition of receptor binding and neutralization of bioactivity by anti-erythropoietin monoclonal antibodies. Blood 1990;75:874-880.
41. Sytkowski AJ, Donahue KA. Immunochemical studies of human erythropoietin using site-specific anti-peptide antibodies. J Biol Chem 1987;262:1161-1165.
42. Feldman L, Heinzerling R, Hillam RP, et al. Four unique monoclonal antibodies to the putative receptor binding domain of erythropoietin inhibit the biological function of the hormone. Exp Hematol 1992;20:64-68.